Key Insights

Highlights

Success Rate

95% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

4.0%

1 terminated out of 25 trials

Success Rate

95.0%

+8.5% vs benchmark

Late-Stage Pipeline

36%

9 trials in Phase 3/4

Results Transparency

53%

10 of 19 completed with results

Key Signals

10 with results95% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (1)
P 1 (2)
P 2 (7)
P 3 (4)
P 4 (5)

Trial Status

Completed19
Unknown2
Active Not Recruiting1
Not Yet Recruiting1
Withdrawn1
Terminated1

Trial Success Rate

95.0%

Benchmark: 86.5%

Based on 19 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT07385495Active Not RecruitingPrimary

OJO-miR: microRNA Expression in Allergic Conjunctivitis.

NCT07171307Not Yet RecruitingPrimary

Treg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therapy

NCT04037891Phase 1Terminated

Topical rVA576 for Treatment of Atopic Keratoconjunctivitis

NCT03709121Phase 1CompletedPrimary

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

NCT00311844Phase 4CompletedPrimary

A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209)

NCT06063044Completed

Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children

NCT03012165Phase 2CompletedPrimary

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

NCT03186755Phase 4UnknownPrimary

Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis

NCT03375775Not ApplicableCompleted

Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children

NCT01289431Phase 2CompletedPrimary

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

NCT04299399UnknownPrimary

Corneal Biomechanical Changes of Allergic Conjunctivitis

NCT02555761CompletedPrimary

Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea

NCT02161146Phase 3CompletedPrimary

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis

NCT01541904Phase 2Withdrawn

Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis

NCT02082262Phase 3CompletedPrimary

AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis

NCT01987765CompletedPrimary

Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

NCT01732757Phase 4CompletedPrimary

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

NCT01470118Phase 4CompletedPrimary

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

NCT00424398Phase 2CompletedPrimary

Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

NCT00422149Phase 3Completed

Twin SUBLIVAC® Grasses Clinical Efficacy Study

Scroll to load more

Research Network

Activity Timeline